Clinicopathological features of homologous recombination-deficient epithelial ovarian cancers: sensitivity to PARP inhibitors, platinum, and survival. [electronic resource]
Producer: 20130305Description: 5675-82 p. digitalISSN:- 1538-7445
- Aged
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Carboplatin -- administration & dosage
- Carcinoma, Ovarian Epithelial
- Combined Modality Therapy
- DNA Breaks, Double-Stranded
- Enzyme Inhibitors -- administration & dosage
- Female
- Homologous Recombination
- Humans
- Kaplan-Meier Estimate
- Middle Aged
- Neoplasms, Glandular and Epithelial -- drug therapy
- Ovarian Neoplasms -- drug therapy
- Paclitaxel -- administration & dosage
- Poly(ADP-ribose) Polymerase Inhibitors
No physical items for this record
Publication Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.